Share this post on:

Product Name: EIF2B epsilon (phospho Ser539) antibody
Applications: WB
Predicted Target Size:
Positive Controls: Recombinant eIF-2B epsilon treated with GSK 3 beta and lambda phosphatase, CHO-T cells transfected with human insulin receptor (IR) +/- insulin
Form Supplied: Liquid
Concentration:
Purification: Immunogen affinity purified
Full Name: eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa
Background: Eukaryotic Initiation Factor 2B (eIF-2B) plays a key role by acting as a guanine nucleotide exchange factor in the initiation of mRNA translation in eukaryotic cells. The activity of eIF-2B is regulated by a wide array of conditions. Stress inhibits its action, while stimulation of protein synthesis results in activation. eIF-2B epsilon, an 82 kDa subunit of eIF-2B, is phosphorylated at serine 539 by glycogen synthase kinase 3 (GSK 3), which leads to inhibition of its guanine nucleotide exchange activity.
Synonyms: EIF-2B, 8893, EIF2Bepsilon, EIF2B epsilon, EIF2B5, CACH, Q13144, LVWM, CLE, EIF2B, 603896, EIF 2B, EIF2B epsilon (phospho S539), EIF2B epsilon (phospho Ser539), EIF2B epsilon (pS539), EIF2B epsilon (pSer539), EIF2B epsilon phospho S539, EIF2B epsilon phos
Cellular Localization:
CAS NO: 364782-34-3
Product: Semagacestat
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Synthetic peptide (Rat) derived from the region of rat eIF-2B epsilon that contains serine 535 (corresponding to serine 539 in the human sequence).
Antigen Species: Human
Species Reactivity: Human, Mouse, Rat
Conjugation: Unconjugated
Storage Buffer: Preservative: 0.05% Sodium Azide; Constituents: PBS, 50% glycerol, 1.0mg/ml BSA (IgG, protease free). pH 7.3
Storage Instruction: Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/22546693?dopt=Abstract

Share this post on: